These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15377972)

  • 1. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
    Schweizer C; Saugy M; Kamber M
    Clin J Sport Med; 2004 Sep; 14(5):312-5. PubMed ID: 15377972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salbutamol and the competitive athlete.
    McKenzie DC
    Clin J Sport Med; 2004 Sep; 14(5):316. PubMed ID: 15377973
    [No Abstract]   [Full Text] [Related]  

  • 3. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
    Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
    Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
    Ventura R; Segura J; Bergés R; Fitch KD; Morton AR; Berruezo S; Jiménez C
    Ther Drug Monit; 2000 Jun; 22(3):277-82. PubMed ID: 10850394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
    Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
    Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futility of current urine salbutamol doping control.
    Heuberger JAAC; van Dijkman SC; Cohen AF
    Br J Clin Pharmacol; 2018 Aug; 84(8):1830-1838. PubMed ID: 29722428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Clin J Sport Med; 2012 Mar; 22(2):140-5. PubMed ID: 22388343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Induced asthma and sport].
    Chenuel B
    Rev Prat; 2020 Nov; 70(9):997-1004. PubMed ID: 33739762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The enigma of inhaled salbutamol and sport: unresolved after 45 years.
    Fitch KD
    Drug Test Anal; 2017 Jul; 9(7):977-982. PubMed ID: 28294577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping.
    McKenzie DC; Fitch KD
    Clin J Sport Med; 2011 Jan; 21(1):46-50. PubMed ID: 21200170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
    Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
    Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
    Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
    Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
    Courlet P; Buclin T; Biollaz J; Mazzoni I; Rabin O; Guidi M
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):469-481. PubMed ID: 35315251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Jacobson GA; Fawcett JP
    Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary and blood concentrations of beta2-agonists in trained subjects: comparison between routes of use.
    Pichon A; Venisse N; Krupka E; Pérault-Pochat MC; Denjean A
    Int J Sports Med; 2006 Mar; 27(3):187-92. PubMed ID: 16541373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control.
    Dickinson J; Hu J; Chester N; Loosemore M; Whyte G
    Clin J Sport Med; 2014 Nov; 24(6):482-9. PubMed ID: 24518370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine concentrations of repetitive doses of inhaled salbutamol.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of inhaled salbutamol in equine urine by ELISA and GC/MS2.
    Eenoo PV; Delbeke FT
    Biomed Chromatogr; 2002 Dec; 16(8):513-6. PubMed ID: 12474214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine concentrations of oral salbutamol in samples collected after intense exercise in endurance athletes.
    Hostrup M; Kalsen A; Auchenberg M; Rzeppa S; Hemmersbach P; Bangsbo J; Backer V
    Drug Test Anal; 2014 Jun; 6(6):528-32. PubMed ID: 24166762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.